Braveheart Bio Strengthens Leadership Bench Ahead of 2026 Global Phase 3 oHCM Trial

New updates have been reported about Braveheart Bio.

Braveheart Bio has expanded its senior leadership team as it prepares to enter late-stage development for its lead hypertrophic cardiomyopathy (HCM) asset, BHB-1893, with a global Phase 3 trial in obstructive HCM planned for 2026. The company promoted Marc Evanchik to Chief Scientific Officer, elevating him from his prior role leading pharmacology and translational medicine, and hired Brittany de Temple as Senior Vice President of Development Operations to build out and scale Braveheart’s clinical execution capabilities. CEO and President Travis Murdoch, M.D., said Evanchik has been central to defining the clinical and mechanistic differentiation of BHB-1893 and that de Temple’s late-stage development experience will be critical as the company transitions into Phase 3.

Evanchik, who has more than 25 years of biotech experience and previously helped advance multiple cardiovascular candidates into registrational studies, will now oversee Braveheart’s scientific strategy from target discovery through late-stage development and joins the executive leadership team alongside the CEO, Chief Development Officer and Chief Financial Officer. His background includes key roles at MyoKardia and Edgewise Therapeutics and substantial contributions to the development of Camzyos (mavacamten), the first commercial cardiac myosin inhibitor—experience directly relevant to Braveheart’s focus on cardiac hypercontractility. De Temple brings over two decades of global clinical operations leadership, most recently as Vice President of Development Operations at Akero Therapeutics, with prior roles at Genentech, Gilead and IQVIA; at Braveheart she will oversee operational strategy and execution for an expanding clinical portfolio. Backed by leading life sciences investors, Braveheart is positioning BHB-1893 as a potential best-in-class therapy that could change the disease course for HCM by targeting precise molecular drivers while aiming for more patient-friendly delivery, underscoring a pivotal period for the company as it moves toward Phase 3 and eventual registrational pathways.